2023
Associations between ABO non‐identical platelet transfusions and patient outcomes—A multicenter retrospective analysis
Bougie D, Reese S, Birch R, Bookwalter D, Mitchell P, Roh D, Kreuziger L, Cable R, Goel R, Gottschall J, Hauser R, Hendrickson J, Hod E, Josephson C, Kahn S, Kleinman S, Mast A, Ness P, Roubinian N, Sloan S, Study‐IV‐Pediatric F. Associations between ABO non‐identical platelet transfusions and patient outcomes—A multicenter retrospective analysis. Transfusion 2023, 63: 960-972. PMID: 36994786, PMCID: PMC10175171, DOI: 10.1111/trf.17319.Peer-Reviewed Original ResearchConceptsPlatelet transfusionsHazard ratioPatient outcomesMulticenter retrospective analysisPlatelet transfusion requirementsGroup O recipientsRecipient's blood groupRisk of mortalitySpecific patient populationsBlood group ARecipient EpidemiologyTransfusion requirementsB recipientsOverall cohortProspective studyO recipientsPatient populationRetrospective analysisPlatelet dosesGroup ATransfusionABO antigensABO groupPatient exposureSignificant association
2020
Optimization of Plerixafor Utilization Based on Peripheral Blood CD34+ Count for Autologous Peripheral Blood Stem-Cell Collection
Gupta G, Perreault S, Seropian S, Tormey C, Hendrickson J. Optimization of Plerixafor Utilization Based on Peripheral Blood CD34+ Count for Autologous Peripheral Blood Stem-Cell Collection. Blood 2020, 136: 41. DOI: 10.1182/blood-2020-140171.Peer-Reviewed Original ResearchPeripheral blood CD34Second doseGroup 2Group 1Peripheral CD34Multiple myelomaPlerixafor groupFirst dayAutologous peripheral blood stem cell collectionPeripheral blood stem cell collectionBlood CD34C chemokine receptor type 4Autologous stem cell mobilizationBlood stem cell collectionTertiary care medical centerChemokine receptor type 4Dose of plerixaforReceptor type 4Stem cell collectionStem cell mobilizationAdult patientsFilgrastim treatmentPhysician's discretionCollection goalRetrospective analysis